D Neuro Amyotrophic Lateral Sclerosis Als

| Record ID | |
|---|--|
| | |
| 1. Gold Standard Diagnosis | |
| Does the patient meet the diagnostic criteria for A | Amyotrophic Lateral Sclerosis (ALS) based |
| on: | |
| (1) Progressive motor impairment documented by history or repeated clinical assessment, preceded by normal motor function; | ○ Yes○ No○ Not certain |
| (2) presence of UMN and LMN signs in at least 1 body region (with UMN and LMN dysfunction noted in the same body region if only one body region is involved) or LMN dysfunction in at least 2 body regions; | YesNoNot certain |
| (3) investigations excluding other disease processes. | YesNoNot certain |
| Does the patient meet the diagnostic criteria for Amyotrophic Lateral Sclerosis (ALS) based on the criteria above? | |
| 2. Type of ALS | |
| Specify the type of ALS in the patient: | ○ Sporadic ALS○ Familial ALS○ Spinal/limb-onset ALS○ Bulbar-onset ALS |
| If you selected "Familial ALS", please specify the genetic mutation if known: | |
| 3. Etiology | |
| What is the suspected or known etiology of ALS in the patient? | ☐ Genetic factors☐ Environmental factors |
| Genetic Factors | ☐ C9orf72 mutation☐ SOD1 mutation☐ Other genetic factors |
| If you selected "Other genetic factors", please specify: | |
| If you selected "Environmental factors", please specify: | |



| 4. Clinical Presentation | |
|--|--|
| Describe the clinical features and symptoms of ALS in the patient: | □ Upper Motor Neuron Signs (e.g., spasticity, hyperreflexia) □ Lower Motor Neuron Signs (e.g., muscle weakness atrophy, fasciculations) □ Bulbar Symptoms (e.g., dysarthria, dysphagia) □ Respiratory Involvement |
| 5. Disease Progression | |
| Please provide information on the current stage and progression of ALS: | Early StageIntermediate StageAdvanced Stage |
| 6. Neurological Assessment Please provide results from relevant neurological | al assessments: |
| Revised ALS Functional Rating Scale (ALSFRS-R) score: | |
| Forced Vital Capacity (FVC) percentage (if measured): | |
| Other neurological assessment (please specify): | |
| 7. Imaging and Diagnostic Tests | |
| Electromyography (EMG) and Nerve Conduction Studies (NCS): | |
| Magnetic Resonance Imaging (MRI) of the brain and spinal cord: | |
| Lumbar Puncture (if performed, specify findings): | |
| Genetic testing (if applicable, specify results): | |
| Other diagnostic tests (please specify): | |
| 8. Treatment and Management | |
| Has the patient undergone any treatment or interventions for ALS? | |
| Yes | ☐ Medications☐ Supportive Care |

₹EDCap°

| Medications (if applicable): | Riluzole Edaravone Sodium phenylbutyrate/taurursodiol Tofersen Symptomatic treatment (e.g., for spasticity, pain) Other |
|--|--|
| If you selected "Other", please specify: | |
| | |
| Supportive Care: | ☐ Physical therapy ☐ Occupational therapy ☐ Speech therapy ☐ Respiratory support (e.g., non-invasive ventilation) ☐ Nutrition and swallowing support ☐ Psychotherapy ☐ Other |
| If you selected "Other", please specify: | |
| | |

₹EDCap°